COPENHAGEN, Denmark, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing on February 5, 2024 of its previously announced public offering of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-fund ...

COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) ...

Financial Performance - For the three months ended June 30, 2023, total operating expenses were $5,677,000, a decrease of 9.3% compared to $6,259,000 for the same period in 2022[5]. - The net loss for the period was $5,683,000, compared to a net loss of $4,768,000 for the same period in 2022, reflecting an increase of 19.2%[5]. - The total comprehensive loss for the six months ended June 30, 2023, was $11,891,000, compared to $12,764,000 for the same period in 2022, showing a slight improvement of 6.9%[5]. - Research and development expenses for the six months ended June 30, 2023, were $6,788,000, down 24% from $8,916,000 in the same period of 2022[5]. - The company reported finance income of $47,000 for the three months ended June 30, 2023, a significant decrease from $1,539,000 in the same period of 2022[5]. Cash and Assets - Cash and cash equivalents decreased to $7,118,000 as of June 30, 2023, down from $13,184,000 at the beginning of the year, representing a decline of 46%[8]. - Total assets decreased to $16,754,000 as of June 30, 2023, from $22,025,000 as of December 31, 2022, a reduction of 24%[8]. - The accumulated deficit increased to $84,257,000 as of June 30, 2023, compared to $72,659,000 at the end of 2022, indicating a rise of 15.9%[8]. Financing and Capital Needs - The company plans to finance cash needs through equity offerings or other capital sources, requiring additional financing by December 2023[18]. - The company raised $5,973,000 from the issuance of shares and exercise of warrants during the six months ended June 30, 2023[12]. - The company entered into a Purchase Agreement to sell up to $40 million of its ordinary shares over a 36-month period, with no sales made as of June 30, 2023[24]. - The company has a financing agreement of up to $20 million with Global Growth Holding Limited as of July 31, 2023[26]. - The company’s current cash position and forecasted cash requirements indicate a need for additional financing to continue operations and product development[17]. Legal Proceedings - As of June 30, 2023, the Company and SSI have agreed to pause ongoing court proceedings and begin out-of-court negotiations[71]. - The Company believes ongoing legal proceedings will not materially impact future financial results[71]. - The Company believes it has strong defenses against SSI's claim regarding the Invention[70]. - The Company does not expect a material impact on its rights to use the Invention for developing and commercializing EVX-01[70]. - The Company intends to vigorously defend against SSI's claim, which it believes is without merit[70]. Going Concern - The company has significant doubt about its ability to continue as a going concern for at least one year from the balance sheet date due to ongoing losses and funding needs[19]. Shareholder Information - The carrying amount of the warrant liability decreased from $573,000 at January 1, 2023, to $402,000 at June 30, 2023, due to remeasurement[46]. - As of June 30, 2023, the number of warrants as a percentage of outstanding ordinary shares was 8.6%, down from 11.0% in 2022[47]. - The company granted 10,000 warrants to an employee on March 15, 2023, which vest over 36 months[50]. - The company sold 3,160,208 ordinary shares represented by ADSs from January 1, 2023, to June 30, 2023, at a volume weighted average price of $1.84 per ADS, generating approximately $6.0 million in gross proceeds[64]. - The company issued 428,572 ordinary shares as a commitment fee of $1.2 million for Lincoln Park's commitment under the Purchase Agreement[24].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...

Exhibit1.1 VEDTÆGTER / ARTICLES OF ASSOCIATION EVAXION BIOTECH A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 2. Kapitalforhold 2. Capital 2.2 Kapitalejers navn og adresse indføres i selskabets ejerbog. Ejerbogen føres af Computershare A/S (CVR-nr. 27088899). 2.3 Ingen aktie har særlige rettigheder og ingen kapitalejer er pligtig at lade sine aktier indløse. 2.3 No share carries any special rights and no shareholder is obliged to let his shares be redeemed. 2.5 Bestyrelsen er i periode ...

Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After todayÂ's presentation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of ...

Evaxion Biotech A/S (EVAX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Corey Davis – LifeSci Advisors Lars Wegner – Chief Executive Officer Jesper Nyegaard Nissen – Interim Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Ahu Demir – Ladenburg Thomas Flaten – Lake Street Operator Greetings, and welcome to the Evaxion Biotech First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer sess ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REP ...

Financial Data and Key Metrics Changes - The company raised net proceeds of $27.9 million from its US IPO in February 2021, contributing to a cash position of $27 million as of March 31, 2021, compared to $5.8 million as of December 31, 2020 [12] - Research and Development expenses increased to $3.9 million for Q1 2021 from $2.5 million in Q1 2020, primarily due to increased spending on ongoing development and higher employee-related expenses [13] - General and administrative expenses were $1.3 million for Q1 2021, down from $2.8 million in Q1 2020, reflecting increased overhead and professional fees related to the IPO [13] - The net loss for Q1 2021 was $4.1 million, or $0.23 loss per share, compared to a net loss of $3.1 million, or $0.20 loss per share, in Q1 2020 [14] Business Line Data and Key Metrics Changes - The recruitment for phase 1 and 2A trials of the lead immune oncology product candidates EVX-01 and EVX-02 is on track, with data readout expected in late Q2 2021 [7] - EVX-01, a peptide-based therapy, showed one complete response and two partial responses out of five patients in early trials [7] - EVX-02, a DNA-based vaccine for adjuvant melanoma, has five patients recruited to date [8] Market Data and Key Metrics Changes - The company is advancing its RAVEN AI platform for vaccine design and development for viral diseases, leveraging experience from cancer research [9][28] - The company is preparing for regulatory filing for clinical trials of EVX-03 in the second half of 2021 [8] Company Strategy and Development Direction - The company aims to move forward with potential phase 2 trials for EVX-01 and EVX-02 based on data readouts, with preparations already underway [22] - The strategy includes exploring various indications for EVX-03, focusing on solid tumors with high mutation rates [20][24] - The company is committed to non-dilutive funding through government grants to support the RAVEN platform [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that existing cash resources will support operations into 2022 [14] - The company anticipates busy months ahead with significant data readouts and potential advancements in clinical trials [10] Other Important Information - The company published a paper in a peer-reviewed journal regarding Staphylococcus aureus, contributing to the understanding of host-pathogen interactions [9] - The company has moved to new headquarters and research facilities in Denmark [10] Q&A Session Summary Question: Expectations for EVX-01 and EVX-02 data updates - Management expects to determine the recommended phase 2 dose for EVX-01 and will provide an immunological picture for EVX-02 to support potential phase 2 decisions [17] Question: Timeline for phase 2 decisions - Management is preparing for potential phase 2 trials but has not communicated specific timelines, aiming to move forward quickly if data supports it [22] Question: Internal investment versus third-party funding for RAVEN - The RAVEN platform is primarily supported by non-dilutive grants, and the company is rapidly advancing its viral platform based on cancer research experience [28]